loader image
Saturday, December 20, 2025
84.8 F
McAllen
- Advertisement -

LEARN MORE ABOUT DR. BILAL BIN HAFEEZ

Community NewsNews
1293

Translate to Spanish or other 102 languages!

Graduate research assistants Emmanuel Anning, Godwin Peasah-Darkwah and Asif Shahriar work in the lab to assist in the development of a treatment for advanced pancreatic cancer. (UTRGV Image Office of Research & New Program Development)

Mega Doctor News

- Advertisement -

Hafeez is the founding member of the first nationally recognized South Texas Center of Excellence in Cancer Immunology at the UTRGV School of Medicine and is an accomplished researcher with a background in immunopharmacology, cancer therapeutics and cancer biology. Hafeez, a Nehtaur, Bijnor, Uttar Pradesh, India native, has earned prestigious grant awards and is an active member of the American Association for Cancer Research and the Indian Association for Cancer Research. His significant contributions to cancer biology and molecular therapeutics have led to his numerous published manuscripts in scientific journals. 

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
School of Medicine earns $1.45M grant for pancreatic cancer research
Next article
Nursing and Allied Health to host new conference dedicated to health careers for students

More Articles

FDA Approves Daily Pill to Treat Low Libido in Women After Menopause

On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved the medication Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65.

Heart Association Highlights 2025’s Major Research Findings

In 2025, cardiovascular investigators worldwide reported findings that could help fill important gaps in preventing and managing conditions including high blood pressure, stroke, heart failure, dangerous blood clots and aortic stenosis.

DHR Health and Brownsville Join Forces on Major Hospital Expansion

The City of Brownsville and DHR Health announced a new public-private partnership to expand DHR Health Brownsville, marking a major investment in local healthcare and economic development

Uniting Experts to Revolutionize Cancer Treatment

More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung.
- Advertisement -

We feature articles about leading professionals in the medical and healthcare industry in the South Texas area. We are your connection to the medical community!

Pick up a copy of our publication on more than 800 locations Valley-wide.

Contact Us

Office (956) 928-1255

Sales (956) 451-4585

info@tbbmega.com

sales@tbbmega.com

Subscribe

© Mega Doctor News 2025

×